Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2.2.1 (Primary Endpoints) Please see the Protocol, Section 2.2.2 (Secondary Endpoints)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. We would like to rely on Advarra as the IRB …
You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.
This study recruits participants directly from Penn Medicine clinics, during time of their clinical biopsies. Up to 40 participants with known or suspected primary or metastatic breast cancer who meet eligibility requirements for this study will undergo FTT PET/CT study imaging. Each PET/CT scan will include an injection of up …
Please refer to Protocol Section 1 (Objectives). Please refer to Protocol Section 14.3 (Analysis of Secondary Endpoints). Please refer to Protocol Section 14.1. (Study Design/Endpoints)
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints)
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced …
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. We would like to rely on CIRB as the IRB of record for this study.
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or …
